Jaguar Health/$JAGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Jaguar Health
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Ticker
$JAGX
Sector
Primary listing
Employees
47
Headquarters
Website
Jaguar Health Metrics
BasicAdvanced
$5.3m
-
-$22.97
0.29
-
Price and volume
Market cap
$5.3m
Beta
0.29
52-week high
$15.48
52-week low
$0.31
Average daily volume
496k
Financial strength
Current ratio
0.5
Quick ratio
0.066
Long term debt to equity
-85.483
Total debt to equity
-233.342
Interest coverage (TTM)
-673.25%
Profitability
EBITDA (TTM)
-43.195
Gross margin (TTM)
67.21%
Net profit margin (TTM)
-464.20%
Operating margin (TTM)
-391.87%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
-61.46%
Return on equity (TTM)
1,112.31%
Valuation
Price to revenue (TTM)
0.083
Price to book
-0.14
Price to tangible book (TTM)
-0.08
Price to free cash flow (TTM)
-0.04
Free cash flow yield (TTM)
-2,482.62%
Free cash flow per share (TTM)
-10.173
Growth
Revenue change (TTM)
-1.52%
Earnings per share change (TTM)
-82.42%
3-year revenue growth (CAGR)
-1.26%
10-year revenue growth (CAGR)
40.25%
10-year earnings per share growth (CAGR)
84.99%
Jaguar Health News
AllArticlesVideos
Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders
Accesswire·3 days ago
Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs
Accesswire·1 week ago
Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Jaguar Health stock?
Jaguar Health (JAGX) has a market cap of $5.3M as of April 23, 2026.
What is the P/E ratio for Jaguar Health stock?
The price to earnings (P/E) ratio for Jaguar Health (JAGX) stock is 0 as of April 23, 2026.
Does Jaguar Health stock pay dividends?
No, Jaguar Health (JAGX) stock does not pay dividends to its shareholders as of April 23, 2026.
When is the next Jaguar Health dividend payment date?
Jaguar Health (JAGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Jaguar Health?
Jaguar Health (JAGX) has a beta rating of 0.29. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.